Comparative Study
doi: 10.1016/s0924-8579(02)00192-9.
The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains
Affiliations
- PMID: 12431875
- DOI: 10.1016/s0924-8579(02)00192-9
Item in Clipboard
Comparative Study
The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains
Int J Antimicrob Agents.
2002 Nov.
Abstract
This study evaluated the in vitro effects of the combination of a carbapenem (imipenem or meropenem) with a quinolone (ciprofloxacin or levofloxacin) using a microbroth dilution chequerboard technique and multidrug-resistant Pseudomonas aeruginosa strains. The ciprofloxacin and meropenem combination was only synergistic against 2 strains (6.2%) and ciprofloxacin and imipenem against 1 strain (3.1%). Levofloxacin and imipenem or meropenem were not synergistic for against any strain. None of the combinations showed an antagonistic effect.
Similar articles
-
In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.BMC Infect Dis. 2016 Aug 24;16(1):444. doi: 10.1186/s12879-016-1785-7. BMC Infect Dis. 2016. PMID: 27553962 Free PMC article.
-
In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia.J Chemother. 1991 Jun;3(3):143-6. doi: 10.1080/1120009x.1991.11739081. J Chemother. 1991. PMID: 1919651
-
Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.Clin Infect Dis. 2005 Feb 15;40 Suppl 2:S105-14. doi: 10.1086/426190. Clin Infect Dis. 2005. PMID: 15712098
-
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Drugs. 2018. PMID: 29230684 Review.
-
Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.J Chemother. 2004 Apr;16 Suppl 2:3-7. doi: 10.1080/1120009x.2004.11782365. J Chemother. 2004. PMID: 15255554 Review. No abstract available.
Cited by
-
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.Front Cell Infect Microbiol. 2022 Mar 15;12:823684. doi: 10.3389/fcimb.2022.823684. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35372099 Free PMC article. Review.
-
Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model.Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00469-20. doi: 10.1128/AAC.00469-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32366710 Free PMC article.
-
Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01150-18. doi: 10.1128/AAC.01150-18. Print 2018 Nov. Antimicrob Agents Chemother. 2018. PMID: 30104278 Free PMC article.
-
Current treatment of pseudomonal infections in the elderly.Drugs Aging. 2009;26(5):363-79. doi: 10.2165/00002512-200926050-00001. Drugs Aging. 2009. PMID: 19552489 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
